Exploring factors related to clinically advanced fibrosis in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis

References

• Cariou B, Byrne CD, Loomba R, et al. Nonalcoholic fatty liver disease as a metabolic disease in humans: a literature review. Diab Obes Metab. 2021;23(5):1069–1083. doi: 10.1111/dom.14322
   PubMed Web of Science ®Google Scholar
• Abenavoli L, Scarlata GGM, Scarpellini E, et al. Metabolic-Dysfunction-associated fatty liver disease and gut microbiota: from fatty liver to dysmetabolic syndrome. Med Kaunas Lith. 2023;59(3):594. doi: 10.3390/medicina59030594
   PubMed Web of Science ®Google Scholar
• Definition & Facts of NAFLD & NASH - NIDDK [Internet]. Natl. Inst. Diabetes Dig. Kidney Dis. [cited 2023 Mar 12]. Available from: https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts.
   Google Scholar
• Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133. doi: 10.1002/hep.29466
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi: 10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Powell EE, Wong V-S, Rinella M. Non-alcoholic fatty liver disease. Lancet Lond Engl. 2021;397(10290):2212–2224. doi: 10.1016/S0140-6736(20)32511-3
   PubMed Web of Science ®Google Scholar
• Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–1965. doi: 10.1097/HEP.0000000000000466
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–1586. doi: 10.1002/hep.28785
   PubMed Web of Science ®Google Scholar
• Younossi Z, Aggarwal P, Shrestha I, et al. The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep Innov Hepatol. 2022;4(9):100525. doi: 10.1016/j.jhepr.2022.100525
   PubMedGoogle Scholar
• Huber Y, Boyle M, Hallsworth K, et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17(10):2085–2092.e1. doi: 10.1016/j.cgh.2018.12.016
   PubMed Web of Science ®Google Scholar
• O’Hara J, Finnegan A, Dhillon H, et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. JHEP Rep Innov Hepatol. 2020;2(5):100142. doi: 10.1016/j.jhepr.2020.100142
   PubMedGoogle Scholar
• Vuppalanchi R, Noureddin M, Alkhouri N, et al. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2021;18(6):373–392. doi: 10.1038/s41575-020-00408-y
   PubMed Web of Science ®Google Scholar
• Brennan PN, Elsharkawy AM, Kendall TJ, et al. Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach. Nat Rev Gastroenterol Hepatol. 2023;20(10):679–688. doi: 10.1038/s41575-023-00796-x
   PubMed Web of Science ®Google Scholar
• Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. doi: 10.1097/HEP.0000000000000323
   PubMed Web of Science ®Google Scholar
• Cusi K, Isaacs S, Barb D, et al. American association of clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and Endocrinology clinical settings: co-sponsored by the American association for the study of liver Diseases (AASLD). Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2022;28:528–562.
   Google Scholar
• Porayko MK, Articolo A, Cerenzia W, et al. Differences in NAFLD/NASH management by provider specialty: opportunities for optimizing multidisciplinary care. J Multidiscip Healthc. 2022;15:1533–1545. doi: 10.2147/JMDH.S367607
   PubMed Web of Science ®Google Scholar
• Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2009;7(10):1104–1112. doi: 10.1016/j.cgh.2009.05.033
   PubMed Web of Science ®Google Scholar
• Scott SC, Goldberg MS, Mayo NE. Statistical assessment of ordinal outcomes in comparative studies. J Clin Epidemiol. 1997;50(1):45–55. doi: 10.1016/S0895-4356(96)00312-5
   PubMed Web of Science ®Google Scholar
• Curcic IB, Berkovic MC, Kuna L, et al. Obesity paradox in chronic liver Diseases: product of bias or a real thing? J Clin Transl Hepatol. 2019;7(3):1–5. doi: 10.14218/JCTH.2019.00029
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Ong JP, Takahashi H, et al. A global survey of physicians knowledge about nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2022;20(6):e1456–e1468. doi: 10.1016/j.cgh.2021.06.048
   PubMed Web of Science ®Google Scholar
• Elsayed A, Ismaiel A, Procopio AC, et al. Noninvasive biochemical markers and surrogate scores in evaluating nonalcoholic steatohepatitis. Minerva Med. 2022;113(5):864–874. doi: 10.23736/S0026-4806.22.08185-X
   PubMedGoogle Scholar
• Novo Nordisk A/S. The effect of semaglutide in Subjects with Non-cirrhotic Non-alcoholic steatohepatitis [internet]. clinicaltrials.gov. 2023 [cited 2023 Apr 12]. Report No.: NCT04822181. Available from: https://clinicaltrials.gov/ct2/show/NCT04822181.
   Google Scholar
• Fullerton AS, Xu J. The proportional odds with partial proportionality constraints model for ordinal response variables. Soc Sci Res. 2012;41(1):182–198. doi: 10.1016/j.ssresearch.2011.09.003
   PubMed Web of Science ®Google Scholar